Keel
Module 4 of 411 min read

Patient Selection and Monitoring

Safe GLP-1 and peptide therapy begins with disciplined patient selection: screening for a personal or family history of medullary thyroid carcinoma or MEN2, prior pancreatitis, and pregnancy, then establishing a baseline workup before initiation. Ongoing monitoring tracks response and adverse effects, while self-sourced or research compounds introduce distinct red flags. This module reviews contraindications, monitoring, documentation, and the boundaries of clinician counseling.

Learning Objectives

  • Identify the labeled contraindications and cautions for GLP-1 receptor agonists, including MTC/MEN2, pancreatitis, and pregnancy.
  • Describe an appropriate baseline workup before initiating therapy.
  • Explain the components of ongoing monitoring during GLP-1 and peptide use.
  • Recognize red flags specific to self-sourced and research-grade compounds.
  • Summarize documentation practices and the boundaries of clinician counseling for off-label and investigational products.

Screening and Contraindications

GLP-1 receptor agonists in this class carry a labeled contraindication in patients with a personal or family history of medullary thyroid carcinoma (MTC) and in those with Multiple Endocrine Neoplasia syndrome type 2 (MEN2). This warning derives from rodent thyroid C-cell tumor findings; while the human relevance remains uncertain, the contraindication is explicit in the labeling and should be screened for by direct history at intake.

A history of pancreatitis warrants caution. The labeling notes that these agents have not been studied in patients with prior pancreatitis, and acute pancreatitis is a recognized adverse event. Patients with prior episodes require an individualized risk discussion, and any active or suspected pancreatitis is a reason not to initiate or to discontinue.

Pregnancy is a further consideration: these agents are generally not recommended during pregnancy, and because meaningful weight loss and altered nutrition can affect a pregnancy, discontinuation is typically advised in advance of a planned conception, consistent with the washout implied by each agent's long half-life. Patients of reproductive potential should be counseled accordingly.

Baseline Workup

A typical baseline captures the information needed to select therapy, dose it, and detect adverse effects later. This commonly includes weight, height, and BMI; blood pressure and heart rate; and a focused history covering thyroid and pancreatic disease, gallbladder disease, gastrointestinal disorders such as gastroparesis, and reproductive status.

Laboratory evaluation is individualized but frequently includes glycemic markers such as A1c and glucose where relevant, renal function, and a lipid panel. A medication reconciliation is important because slowed gastric emptying can alter the absorption of some oral drugs, and patients on insulin or sulfonylureas may need those agents adjusted to reduce hypoglycemia risk.

Documenting the indication, the baseline values, and the rationale for the chosen agent establishes the reference point against which later response and adverse effects are judged. For patients arriving already using a self-sourced product, the baseline also captures what they report using and at what dose.

Ongoing Monitoring

Monitoring during therapy tracks both efficacy and safety. Efficacy monitoring follows the indication—weight trajectory, glycemic control, or other target measures—at intervals frequent enough to guide titration decisions. Response that plateaus or fails to materialize prompts reassessment of adherence, technique, and product before escalating.

Safety monitoring centers on the gastrointestinal adverse effects that dominate this class and on the sentinel events the labeling highlights: signs of pancreatitis, gallbladder disease, and, for at-risk patients, symptoms suggesting thyroid pathology such as a neck mass, dysphagia, or persistent hoarseness. Hydration and renal function deserve attention when vomiting or diarrhea is significant.

For peptides used outside GLP-1 therapy, monitoring is more heterogeneous and often lacks a regulatory framework. Many such compounds are investigational, without established human dosing or long-term safety data, and monitoring is necessarily driven by the specific agent and the clinical context rather than by an approved label.

Red Flags With Self-Sourced and Research Compounds

A growing number of patients arrive already using compounds obtained from research-chemical vendors, compounding sources, or online marketplaces. These products are frequently labeled for research use only and are not manufactured under the quality controls that apply to approved drugs, so identity, concentration, purity, and sterility cannot be assumed.

Concrete red flags include products with no verifiable labeling, concentrations that do not match the container, reconstitution done under non-sterile conditions, and reuse or sharing of vials and needles. Injection-site reactions, unexpected systemic symptoms, or effects out of proportion to the stated dose may all point to a mislabeled or contaminated product rather than a pharmacologic effect.

The clinical priority is patient safety over judgment. Eliciting an accurate history of what a patient is actually using—without stigma—allows the clinician to counsel on risk, screen for adverse effects, and document the situation honestly. Many of these compounds are investigational, and their unapproved status should be stated plainly.

Documentation and Counseling Boundaries

Documentation should reflect the indication, the informed-consent discussion, the off-label or investigational nature of the product where applicable, and the counseling provided. Recording what the patient reports using, the advice given, and the patient's understanding protects both the patient and the clinician and creates continuity for future visits.

There is an important boundary between describing published labels and common practice and directing an individual toward a specific unapproved regimen. Explaining what a label states, what a class does, and what risks a practice carries is education; issuing a personalized dosing directive for a compounded or research product moves into a different domain of clinical and regulatory responsibility.

Counseling is most defensible when it is candid about the limits of the evidence, neutral about practices the clinician did not initiate, and clear about red flags that should prompt the patient to seek care. When a patient's chosen course carries risk the clinician cannot mitigate, documenting the discussion and the recommendation is the appropriate response.

Knowledge Check

Self-graded and private: answers are checked on this page only and nothing is saved or submitted.

  1. 1. Which history is a labeled contraindication to GLP-1 receptor agonists in this class?

    • A family history of type 2 diabetes
    • A personal or family history of medullary thyroid carcinoma or MEN2
    • A history of seasonal allergies
    • Prior use of metformin

  2. 2. Why does slowed gastric emptying matter during the baseline medication reconciliation?

    • It has no effect on other medications
    • It can alter the absorption of some oral drugs
    • It increases the potency of injectable peptides
    • It only affects intravenous medications

  3. 3. Which symptom in an at-risk patient should prompt evaluation for thyroid pathology?

    • Mild transient nausea
    • A neck mass, dysphagia, or persistent hoarseness
    • Early satiety
    • Occasional constipation

  4. 4. Which is a red flag associated with self-sourced or research compounds?

    • A product concentration that matches its labeling
    • Sterile reconstitution technique
    • No verifiable labeling or a concentration that does not match the container
    • Use of a single-patient vial

  5. 5. What distinguishes acceptable clinician counseling from crossing a boundary?

    • Describing labels and common practice is education, while directing a personalized unapproved regimen is not
    • There is no meaningful distinction
    • Counseling must always endorse the patient's chosen product
    • Documentation is unnecessary for off-label discussions

Related Reading and Tools

For educational purposes only. Not medical advice.